068270.KS Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 02:30):

Celltrion, Inc., together with its subsidiaries, develops and produces therapeutics based on proteins including oncology treatment drugs in South Korea...

Stats
Today's Volume	497 684
Average Volume	653 587
Market Cap	37 700.85B
EPS	KRW0 ( 2024-02-29 )
Next earnings date	( KRW1 008.85 ) 2024-05-05
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	40.87
ATR14	KRW125.22 (0.07%)

Volume Correlation

Long: -0.15 (neutral)

Short: -0.88 (strong negative)

Signal:(35.466) Neutral

Celltrion, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Celltrion, Inc. Correlation - Currency/Commodity

0.52
( weak )

0.45
( neutral )

-0.50
( weak negative )

0.40
( neutral )

-0.65
( weak negative )

-0.22
( neutral )

Celltrion, Inc. Financials

Annual	2023
Revenue:	KRW2 176.43B
Gross Profit:	KRW2 176.43B (100.00 %)
EPS:	KRW3 658.73

Q4	2023
Revenue:	KRW382.60B
Gross Profit:	KRW382.60B (100.00 %)
EPS:	KRW7.20

Q3	2023
Revenue:	KRW672.29B
Gross Profit:	KRW370.35B (55.09 %)
EPS:	KRW1 570.60

Q2	2023
Revenue:	KRW523.98B
Gross Profit:	KRW276.17B (52.71 %)
EPS:	KRW1 034.63

Financial Reports:

No articles found.

Celltrion, Inc.

Celltrion, Inc., together with its subsidiaries, develops and produces therapeutics based on proteins including oncology treatment drugs in South Korea. The company markets Remsima, Truxima, and Herzuma products; generic pharmaceuticals; covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 for the treatment of asthma and urticaria that is in phase 1 clinical trial; CT-P17 for the treatment of rheumatoid arthritis, psoriatic arthritis, and IBD, which is in phase 3 clinical trial; CT-P16 for the treatment of metastatic colorectal cancer and breast cancer that is in phase 3 clinical trial; CT-P41 for the treatment of osteoporosis and bone loss, which is in phase 1 clinical trial; CT-P43 for the treatment of psoriasis, crohn's disease, and ulcerative colitis that is in phase 3 clinical trial; CT-P42 for the treatment of diabetic macular edema, which is in phase 3 clinical trial; CT-P27 for the treatment of pandemic/seasonal influenza that is in phase 2 clinical trial; CT-P59 for the treatment of COVID-19, which is in phase 3 clinical trial; and CT-G20 for the treatment of Cardiomyopathy that is in phase 1 clinical trial. Celltrion, Inc. has a partnership with Inhalon Biopharma, Inc. to develop IN-006, an inhaled form of regdanvimab for treating patients with COVID-19. The company was founded in 2002 and is headquartered in Incheon, South Korea.